Loading Sign Up for
Dosing
Reminders Loading

Indication

NGENLA is a prescription medicine that contains a form of human growth hormone, like the growth hormone made by the human body, for children 3 years of age and older who are not growing because of low or no growth hormone levels.

NGENLA dosingOnce-weekly dosing means 6 fewer injection days each week versus daily dosing.
Once-weekly NGENLA comes in multiple strengths in an easy-to-use, * prefilled, disposable pen

NGENLA pens come in 2 dosage strengths—24 mg or 60 mg. Each pen comes prefilled with the strength that is right for your child, as prescribed by his or her doctor. Every pen contains multiple weekly doses.

*NGENLA is available in prefilled pens with a low injection volume (<1 mL), a fine needle gauge, and no reconstitution required.

Explore the pen by hovering over the green spots. 

Pen cap

Dose strength
This number tells you the strength of the medication

Dose Strength

Dose window
The injection dose is displayed in milligrams

Dose window

Dose knob
Turn to set the dose

Dose knob

Injection button

Medicine
The NGENLA pen is prefilled and premixed. Do not inject the medicine if it is cloudy 
or dark yellow, or if you see flakes or particles within the medicine window

Medicine

Expiration date
Do not use NGENLA after the date stamped

Expiration

Cartridge holder

Needle attachment
You will attach a new sterile needle here for each dose. Discard the needle after each injection

Needle attachment

Pen Cap

Dose strength
This number tells you the strength of the medication

Dose Strength

Medicine
The NGENLA pen is prefilled and premixed. Do not inject the medicine if it is cloudy 
or dark yellow, or if you see flakes or particles within the medicine window

Medicine

Dose knob
Turn to set the dose

Dose knob

Injection button

Dose window
The injection dose is displayed in milligrams

Dose window

Expiration date
Do not use NGENLA after the date stamped

Expiration
Cartridge holder

Needle attachment
You will attach a new sterile needle here for each dose. Discard the needle after each injection

Needle attachment
The following needles can be used with NGENLA pens:

Novo Nordisk®, NovoFine® Plus

Novo Nordisk®, NovoFine®

Becton Dickinson and Company, 
BD Ultra-Fine™ or BD Micro-Fine™

Pen needles are not included with the NGENLA pen shipments. You will need a prescription from your doctor to get pen needles up to a length of 8 mm from your pharmacy. Talk with your child's doctor about the right needle for him or her.

Every pen shipment comes with detailed Instructions for Use. Be sure that these instructions are followed every time a dose is given. Use a new needle for each injection. Always check the dose window to be sure that the correct dose is set.

Trademarks are owned by their respective companies.

Easy to use with a low injection volume for pediatric patients 
(<1 mL), a fine needle gauge (31G-32G), and no reconstitution required
MyNgenla Plan

After you are prescribed your dose, pen size, and treatment duration, this tool helps you to see how many pens are needed to meet your dosing needs, including when to use 2 pens.

It is not to determine treatment or calculate your NGENLA dose.

By completing the following information, you will receive a PDF to help make the most of all the medicine and minimize waste.

NGENLA storage

Store in the original carton and away from direct sunlight

Before first use, NGENLA should be stored in a refrigerator at 36°F to 46°F (2°C to 8°C). After first use of NGENLA, the pen should continue to be stored in the refrigerator for up to 28 days

Do not freeze NGENLA or expose NGENLA to heat. Do not use NGENLA if it has been frozen

Always remove and safely discard the needle after each injection. Store the NGENLA prefilled pen without an injection needle attached. Replace the cap on your prefilled pen when it is not in use

Do not use the prefilled pen for
 more than 28 days after first use. 
Do not use beyond its 
expiration date

Unused prefilled pens may be used until the expiration date printed on the carton only if the pen has been kept in the refrigerator

Important Safety Information & Use

Important Safety
Information & Use

INDICATION
NGENLA is a prescription medicine that contains a form of human growth hormone, like the growth hormone made by the human body, for children 3 years of age and older who are not growing because of low or no growth hormone levels.
IMPORTANT SAFETY INFORMATION
Do not use NGENLA if:
  • your child has a critical illness caused by certain types of heart or stomach surgery, trauma or breathing problems.
  • your child is allergic to somatrogon-ghla or any of the ingredients in NGENLA.
  • your child has closed bone growth plates.
  • your child has cancer or other tumors.
  • your child’s healthcare provider tells you that your child has certain types of eye problems caused by diabetes.
  • your child has Prader-Willi syndrome, is severely obese, or has breathing problems including sleep apnea (briefly stopping breathing during sleep).
Before using NGENLA, tell your child’s healthcare provider about all of your child’s medical conditions, including if your child:
  • has had heart or stomach surgery, trauma or serious breathing (respiratory) problems.
  • has had a history of problems breathing while they slept.
  • has or has had cancer or any tumor.
  • has diabetes.
  • is pregnant or plans to become pregnant. It is not known if NGENLA will harm your child’s unborn baby. Talk to your child’s healthcare provider if your child is pregnant or plans to become pregnant.
  • is breastfeeding or plans to breastfeed. It is not known if NGENLA passes into breast milk. You and your child’s healthcare provider should decide if they will take NGENLA while breastfeeding.
Tell your child’s healthcare provider about all the medicines your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements. NGENLA may affect how other medicines work, and other medicines may affect how NGENLA works.

NGENLA may cause serious side effects, including:
  • high risk of death in people who have critical illnesses because of heart or stomach surgery, trauma or serious breathing (respiratory) problems.
  • serious allergic reactions. Get medical help right away if your child has the following symptoms: swelling of the face, lips, mouth, or tongue, trouble breathing, wheezing, severe itching, skin rashes, redness, or swelling, dizziness or fainting, fast heartbeat or pounding in the chest, sweating.
  • increased risk of growth of cancer or a tumor that is already present and increased risk of the return of cancer or a tumor in people who were treated with radiation to the brain or head as children and who developed low growth hormone problems. Your child’s healthcare provider will need to monitor your child for a return of cancer or a tumor. Contact your child’s healthcare provider if your child starts to have headaches, or has changes in behavior, changes in vision, or changes in moles, birthmarks, or the color of the skin.
  • new or worsening high blood sugar or diabetes. Your child’s blood sugar may need to be monitored during treatment with NGENLA.
  • increase in pressure inside the skull. If your child has headaches, eye problems, nausea or vomiting, contact your child’s healthcare provider.
  • your child’s body holding too much fluid (fluid retention) such as swelling in the hands and feet, pain in the joints or muscles or nerve problems that cause pain, burning or tingling in the hands, arms, legs and feet. Fluid retention can happen in children during treatment with NGENLA. Tell your child’s healthcare provider if your child has any of these signs or symptoms of fluid retention.
  • decrease in a hormone called cortisol. Your child’s healthcare provider will do blood tests to check your child’s cortisol levels. Tell your child’s healthcare provider if your child has severe fatigue, dizziness, weakness, vomiting, dehydration, or weight loss.
  • decrease in thyroid hormone levels. Decreased thyroid hormone levels may affect how well NGENLA works. Your child’s healthcare provider will do blood tests to check your child’s hormone levels.
  • hip and knee pain or limp (slipped capital femoral epiphysis). This may lead to a serious condition where bone tissue dies due to a lack of blood supply (osteonecrosis). Get medical help for your child right away if your child develops a limp or has hip or knee pain.
  • worsening of curvature of the spine (scoliosis). If your child has scoliosis, your child will need to be checked often for an increase in the curve of the spine.
  • severe and constant stomach (abdominal) pain. This could be a sign of pancreatitis. Tell your child’s healthcare provider if your child has any new abdominal pain.
  • loss of fat and tissue weakness in the area of skin you inject. Talk to your child’s healthcare provider about rotating the areas where you inject NGENLA.
  • high risk of sudden death in children with Prader-Willi syndrome who are severely obese or have breathing problems, including sleep apnea.
  • increase in phosphorus, alkaline phosphatase and parathyroid hormone levels in the blood. Your child’s healthcare provider will do blood tests to check this.
The most common side effects (≥5%) of NGENLA include: injection site reactions (such as pain, swelling, rash, itching, bleeding), common cold, headache, fever, low red blood cells (anemia), cough, vomiting, decrease in thyroid hormone levels, stomach (abdominal) pain, rash, throat pain.

This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.

© 2025 Pfizer Inc. All rights reserved.
PP-SMT-USA-0599